Patient characteristics before and after propensity score matching
| Characteristic name . | Before propensity score matching . | After propensity score matching . | ||||
|---|---|---|---|---|---|---|
| DOAC . | LMWH . | SMD . | DOAC . | LMWH . | SMD . | |
| (n = 727) . | (n = 373) . | (n = 317) . | (n = 317) . | |||
| Demographics | ||||||
| Age at index, mean | 66.6 ± 10.8 | 61.7 ± 12.9 | 0.41 | 63.3 ± 10.9 | 63.2 ± 12.2 | 0.01 |
| Male | 349 (48.0) | 165 (44.2) | 0.08 | 147 (46.4) | 145 (45.7) | 0.01 |
| White | 495 (68.1) | 245 (65.7) | 0.05 | 217 (68.5) | 210 (66.2) | 0.05 |
| African American | 80 (11.0) | 35 (9.3) | 0.05 | 36 (11.4) | 30 (9.5) | 0.06 |
| Hispanic | 25 (3.5) | 21 (5.8) | 0.11 | 10 (3.2) | 12 (3.8) | 0.03 |
| Asian | 23 (3.2) | 14 (3.8) | 0.03 | 7 (2.2) | 6 (1.9) | 0.02 |
| Index venous thromboembolism | ||||||
| PE | 445 (61.2) | 243 (65.1) | 0.08 | 202 (63.7) | 205 (64.7) | 0.02 |
| Acute embolism and thrombosis of deep veins of lower extremity | 358 (49.2) | 172 (46.1) | 0.06 | 145 (45.7) | 145 (45.7) | 0.00 |
| Physical exam | ||||||
| BMI ≥35 kg/m2 | 57 (7.8) | 30 (8.0) | 0.01 | 23 (7.3) | 25 (7.9) | 0.02 |
| Laboratory values | ||||||
| Hemoglobin <10 g/dL | 398 (54.7) | 234 (62.7) | 0.16 | 190 (59.9) | 194 (61.2) | 0.03 |
| Leukocytes >11 × 103/mL | 406 (55.8) | 199 (53.4) | 0.05 | 179 (56.5) | 170 (53.6) | 0.06 |
| Platelets >350 ×109/L | 383 (52.7) | 216 (57.9) | 0.11 | 180 (56.8) | 184 (58.0) | 0.03 |
| LMWH type | ||||||
| Enoxaparin | — | 351 (94.1) | — | — | 295 (93.1) | — |
| Dalteparin | — | 10 (2.7) | — | — | 10 (3.2) | — |
| Tinzaparin | — | 10 (2.7) | — | — | 10 (3.2) | — |
| Bemiparin | — | 10 (2.7) | — | — | 10 (3.2) | — |
| DOAC type | ||||||
| Apixaban | 528 (72.6) | — | — | 218 (68.8) | — | — |
| Rivaroxaban | 221 (30.4) | — | — | 106 (33.4) | — | — |
| Dabigatran | 10 (1.4) | — | — | 10 (3.2) | — | — |
| Edoxaban | 10 (1.4) | — | — | 10 (3.2) | — | — |
| ICI agent | ||||||
| Pembrolizumab | 402 (55.3) | 182 (48.8) | 0.13 | 164 (51.7) | 164 (51.7) | 0.00 |
| Nivolumab | 215 (29.6) | 144 (38.6) | 0.19 | 113 (35.6) | 111 (35.0) | 0.01 |
| Ipilimumab | 84 (11.6) | 48 (12.9) | 0.04 | 45 (14.2) | 38 (12.0) | 0.07 |
| Durvalumab | 58 (8.0) | 14 (3.8) | 0.18 | 10 (3.2) | 14 (4.4) | 0.07 |
| Atezolizumab | 62 (8.5) | 31 (8.3) | 0.01 | 31 (9.8) | 26 (8.2) | 0.06 |
| Cancer type | ||||||
| Head and neck | 20 (2.8) | 11 (2.9) | 0.01 | 13 (4.1) | 10 (3.2) | 0.05 |
| GI and hepatobiliary | 135 (18.6) | 80 (21.4) | 0.07 | 66 (20.8) | 65 (20.5) | 0.01 |
| Lung | 343 (47.2) | 161 (43.2) | 0.08 | 150 (47.3) | 143 (45.1) | 0.04 |
| Melanoma | 67 (9.2) | 40 (10.7) | 0.05 | 33 (10.4) | 33 (10.4) | 0.00 |
| Breast | 58 (8.0) | 29 (7.8) | 0.01 | 25 (7.9) | 26 (8.2) | 0.01 |
| Gynecologic | 59 (8.1) | 34 (9.1) | 0.04 | 31 (9.8) | 29 (9.1) | 0.02 |
| Prostate and testicular | 46 (6.3) | 14 (3.8) | 0.12 | 10 (3.2) | 12 (3.8) | 0.03 |
| Urinary tract | 123 (16.9) | 75 (20.1) | 0.08 | 50 (15.8) | 60 (18.9) | 0.08 |
| Hematologic | 30 (4.1) | 26 (7.0) | 0.12 | 20 (6.3) | 18 (5.7) | 0.03 |
| Metastatic disease | ||||||
| Lymph nodes | 290 (39.9) | 150 (40.2) | 0.01 | 123 (38.8) | 129 (40.7) | 0.04 |
| Respiratory and digestive organs | 351 (48.3) | 224 (60.1) | 0.24 | 180 (56.8) | 180 (56.8) | 0.00 |
| Other and unspecified sites | 436 (60.0) | 250 (67.0) | 0.15 | 203 (64.0) | 206 (65.0) | 0.02 |
| Characteristic name . | Before propensity score matching . | After propensity score matching . | ||||
|---|---|---|---|---|---|---|
| DOAC . | LMWH . | SMD . | DOAC . | LMWH . | SMD . | |
| (n = 727) . | (n = 373) . | (n = 317) . | (n = 317) . | |||
| Demographics | ||||||
| Age at index, mean | 66.6 ± 10.8 | 61.7 ± 12.9 | 0.41 | 63.3 ± 10.9 | 63.2 ± 12.2 | 0.01 |
| Male | 349 (48.0) | 165 (44.2) | 0.08 | 147 (46.4) | 145 (45.7) | 0.01 |
| White | 495 (68.1) | 245 (65.7) | 0.05 | 217 (68.5) | 210 (66.2) | 0.05 |
| African American | 80 (11.0) | 35 (9.3) | 0.05 | 36 (11.4) | 30 (9.5) | 0.06 |
| Hispanic | 25 (3.5) | 21 (5.8) | 0.11 | 10 (3.2) | 12 (3.8) | 0.03 |
| Asian | 23 (3.2) | 14 (3.8) | 0.03 | 7 (2.2) | 6 (1.9) | 0.02 |
| Index venous thromboembolism | ||||||
| PE | 445 (61.2) | 243 (65.1) | 0.08 | 202 (63.7) | 205 (64.7) | 0.02 |
| Acute embolism and thrombosis of deep veins of lower extremity | 358 (49.2) | 172 (46.1) | 0.06 | 145 (45.7) | 145 (45.7) | 0.00 |
| Physical exam | ||||||
| BMI ≥35 kg/m2 | 57 (7.8) | 30 (8.0) | 0.01 | 23 (7.3) | 25 (7.9) | 0.02 |
| Laboratory values | ||||||
| Hemoglobin <10 g/dL | 398 (54.7) | 234 (62.7) | 0.16 | 190 (59.9) | 194 (61.2) | 0.03 |
| Leukocytes >11 × 103/mL | 406 (55.8) | 199 (53.4) | 0.05 | 179 (56.5) | 170 (53.6) | 0.06 |
| Platelets >350 ×109/L | 383 (52.7) | 216 (57.9) | 0.11 | 180 (56.8) | 184 (58.0) | 0.03 |
| LMWH type | ||||||
| Enoxaparin | — | 351 (94.1) | — | — | 295 (93.1) | — |
| Dalteparin | — | 10 (2.7) | — | — | 10 (3.2) | — |
| Tinzaparin | — | 10 (2.7) | — | — | 10 (3.2) | — |
| Bemiparin | — | 10 (2.7) | — | — | 10 (3.2) | — |
| DOAC type | ||||||
| Apixaban | 528 (72.6) | — | — | 218 (68.8) | — | — |
| Rivaroxaban | 221 (30.4) | — | — | 106 (33.4) | — | — |
| Dabigatran | 10 (1.4) | — | — | 10 (3.2) | — | — |
| Edoxaban | 10 (1.4) | — | — | 10 (3.2) | — | — |
| ICI agent | ||||||
| Pembrolizumab | 402 (55.3) | 182 (48.8) | 0.13 | 164 (51.7) | 164 (51.7) | 0.00 |
| Nivolumab | 215 (29.6) | 144 (38.6) | 0.19 | 113 (35.6) | 111 (35.0) | 0.01 |
| Ipilimumab | 84 (11.6) | 48 (12.9) | 0.04 | 45 (14.2) | 38 (12.0) | 0.07 |
| Durvalumab | 58 (8.0) | 14 (3.8) | 0.18 | 10 (3.2) | 14 (4.4) | 0.07 |
| Atezolizumab | 62 (8.5) | 31 (8.3) | 0.01 | 31 (9.8) | 26 (8.2) | 0.06 |
| Cancer type | ||||||
| Head and neck | 20 (2.8) | 11 (2.9) | 0.01 | 13 (4.1) | 10 (3.2) | 0.05 |
| GI and hepatobiliary | 135 (18.6) | 80 (21.4) | 0.07 | 66 (20.8) | 65 (20.5) | 0.01 |
| Lung | 343 (47.2) | 161 (43.2) | 0.08 | 150 (47.3) | 143 (45.1) | 0.04 |
| Melanoma | 67 (9.2) | 40 (10.7) | 0.05 | 33 (10.4) | 33 (10.4) | 0.00 |
| Breast | 58 (8.0) | 29 (7.8) | 0.01 | 25 (7.9) | 26 (8.2) | 0.01 |
| Gynecologic | 59 (8.1) | 34 (9.1) | 0.04 | 31 (9.8) | 29 (9.1) | 0.02 |
| Prostate and testicular | 46 (6.3) | 14 (3.8) | 0.12 | 10 (3.2) | 12 (3.8) | 0.03 |
| Urinary tract | 123 (16.9) | 75 (20.1) | 0.08 | 50 (15.8) | 60 (18.9) | 0.08 |
| Hematologic | 30 (4.1) | 26 (7.0) | 0.12 | 20 (6.3) | 18 (5.7) | 0.03 |
| Metastatic disease | ||||||
| Lymph nodes | 290 (39.9) | 150 (40.2) | 0.01 | 123 (38.8) | 129 (40.7) | 0.04 |
| Respiratory and digestive organs | 351 (48.3) | 224 (60.1) | 0.24 | 180 (56.8) | 180 (56.8) | 0.00 |
| Other and unspecified sites | 436 (60.0) | 250 (67.0) | 0.15 | 203 (64.0) | 206 (65.0) | 0.02 |
BMI, body mass index; SMD, standardized mean difference.
Note that TriNetX does not report exact values for samples >10 to protect patient identity. Values of 10 or less were represented as 10 in the table.